Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indoximod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (L)-1-Methyltryptophan SCHEMBL19993 | 1.00 | MAPT (0.71) | MAPTALDH1A1RECQLGPR84HTR2A | |
| 1-Methyltryptophan SCHEMBL14202956 | 1.00 | MAPT (0.71) | MAPTALDH1A1RECQLGPR84HTR2A | |
| Indoximod SCHEMBL29349777 | 1.00 | MAPT (0.71) | MAPTALDH1A1RECQLGPR84HTR2A | |
| 1-Methyltryptophan SCHEMBL19992 | 1.00 | MAPT (0.71) | MAPTALDH1A1RECQLGPR84HTR2A | |
| Indoximod SCHEMBL23668055 | 0.99 | MAPT (0.69) | MAPTALDH1A1RECQLGPR84HTR2A | |
| Indoximod SCHEMBL18395435 | 0.99 | MAPT (0.69) | MAPTALDH1A1RECQLGPR84HTR2A | |
| Indoximod SCHEMBL30025427 | 0.99 | MAPT (0.69) | MAPTALDH1A1RECQLGPR84HTR2A | |
| 1-Methyltryptophan SCHEMBL23668056 | 0.99 | MAPT (0.69) | MAPTALDH1A1RECQLGPR84HTR2A | |
| 1-Methyltryptophan SCHEMBL20137858 | 0.99 | MAPT (0.69) | MAPTALDH1A1RECQLGPR84HTR2A | |
| (L)-1-Methyltryptophan SCHEMBL31387967 | 0.99 | MAPT (0.69) | MAPTALDH1A1RECQLGPR84HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1893 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057015-A | Cell therapeutic preparation based on tumor specific antigen and application of cell therapeutic preparation in solid tumor | 臻辉生物技术(河南)有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026090266-A2 | IONIZABLE LIPID PRODRUG COMPOUNDS AND LIPID NANOPARTICLES (LNPS) COMPRISING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2026-02-19 | — | — | US | claimed |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | claimed |
| US-12527872-B2 | PEGylated ICD inducer-IDO inhibitor nanoconjugate, and preparation method and use thereof | SHANDONG UNIVERSITY (CN) | 2026-01-20 | — | — | US | claimed |
| CN-120154735-A | Polyamino acid composite material, preparation method thereof and anti-tumor drug | 中国科学院长春应用化学研究所 | 2025-06-17 | — | — | CN | claimed |
| US-12280047-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | claimed |
| CN-119591587-A | EGFR dependent small molecule conjugate-1, 3, 4, preparation method and application thereof | 江苏省中国科学院植物研究所 | 2025-03-11 | — | — | CN | claimed |
| CN-116251062-B | Preparation method and application of bacterial membrane-liposome drug-loading system | 南通大学 | 2024-12-17 | — | — | CN | claimed |
| WO-2011007135-A1 | USE OF PRO-INFLAMMATORY COMPOUNDS FOR PROMOTING BONE FORMATION | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-01-20 | — | — | WO | claimed |
| EP-2177601-A1 | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | Medical College of Georgia Research Institute, Inc (US) | 2010-04-21 | — | — | EP | claimed |
| US-7598287-B2 | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2009-10-06 | — | — | US | claimed |
| US-20090123420-A1 | Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2009-05-14 | — | — | US | claimed |
| US-20090081155-A1 | Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2009-03-26 | — | — | US | claimed |
| EP-1501918-A4 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | MED COLLEGE GEORGIA RES INST (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050186289-A1 | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2005-08-25 | — | — | US | claimed |
| EP-1501918-A1 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | Medical College Of Georgia Research Institute, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003087347-A1 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030194803-A1 | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | MAPT 2693/4885ALDH1A1 1966/4885RECQL 1045/4885 |
| US-12280047-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | MAPT 3308/4885ALDH1A1 553/4885RECQL 1635/4885 |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | FN1, MATR3, COL14A1 | MAPT 2107/4885ALDH1A1 3744/4885RECQL 4001/4885 |
| US-12527872-B2 | PEGylated ICD inducer-IDO inhibitor nanoconjugate, and preparation method and use thereof | IDO1, IDO2, TDO2 | MAPT 1624/4885ALDH1A1 389/4885RECQL 4476/4885 |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | CXCL12, CXCR4, CXCR5 | MAPT 3565/4885ALDH1A1 3405/4885RECQL 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.